摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2-Diisopropylthiiran | 24653-49-4

中文名称
——
中文别名
——
英文名称
2,2-Diisopropylthiiran
英文别名
2,2-diisopropyl-thiirane;2,2-Di(propan-2-yl)thiirane
2,2-Diisopropylthiiran化学式
CAS
24653-49-4
化学式
C8H16S
mdl
——
分子量
144.281
InChiKey
HPGQCBAUDPQMGS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    169.7±9.0 °C(Predicted)
  • 密度:
    0.928±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    25.3
  • 氢给体数:
    0
  • 氢受体数:
    1

反应信息

  • 作为产物:
    参考文献:
    名称:
    开链脂族硫酮和重氮甲烷;1,3,4-噻二唑啉与硫代羰基酰化物的反应
    摘要:
    重氮甲烷在两个方向上加成R 2 C = S,R =乙基,丙基,异丙基,叔丁基;区域异构体比例对R和溶剂极性的依赖性揭示了取向力的性质。由N 3从1,3,4-噻二唑啉中挤出产生的硫酮S-甲基化物经历1,4-H移位或电环化。
    DOI:
    10.1016/s0040-4039(01)93419-7
点击查看最新优质反应信息

文献信息

  • ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY
    申请人:Tamura Yuusuke
    公开号:US20120015961A1
    公开(公告)日:2012-01-19
    The present invention provides, for example, a compound of the following formula (I): wherein R 1 is substituted amino and the like, R 2 is halogen and the like, R 3 is substituted or unsubstituted lower alkyl and the like, R A and R B are each independently hydrogen, substituted or unsubstituted lower alkyl and the like, R C and R D are each independently hydrogen, substituted or unsubstituted lower alkyl, or R C and R D together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle, and ring A is a carbocycle or a heterocycle, its pharmaceutically acceptable salt, or a solvate thereof as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-βproteins.
    本发明提供了以下式(I)的化合物,例如: 其中R 1 是取代基等, R 2 是卤素等, R 3 是取代或未取代的较低烷基等, R A 和R B 各自独立地是氢、取代或未取代的较低烷基等, R C 和R D 各自独立地是氢、取代或未取代的较低烷基,或R C 和R D 与它们连接的碳原子一起可以形成取代或未取代的碳环,以及 环A是碳环或杂环, 其药学上可接受的盐,或其溶剂合物作为由淀粉样蛋白β的产生、分泌和/或沉积引起的疾病的治疗剂。
  • AMINOTHIAZINE OR AMINOOXAZINE DERIVATIVE HAVING AMINO LINKER
    申请人:Masui Moriyasu
    公开号:US20120238557A1
    公开(公告)日:2012-09-20
    The present invention provide a medicament for treating the diseases induced by production, secretion or deposition of amyloid-β proteins, for example, a compound of the following formula (I) wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5 , X, L 1 , L 2 , A, ring B and the dotted line are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.
    本发明提供了一种治疗由淀粉样蛋白β的产生、分泌或沉积引起的疾病的药物,例如以下式(I)的化合物,其中R1、R2a、R2b、R3、R4、R5、X、L1、L2、A、环B和虚线在规范中有定义,其药学上可接受的盐或溶剂化合物。
  • FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP
    申请人:Yoshida Syuhei
    公开号:US20120245155A1
    公开(公告)日:2012-09-27
    The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-βproteins. A compound of the formula (I): wherein R 1 , R 2a , R 2b , R 3 , R 4 , R 5a , R 5b , R 6a , R 6b , X, Y, Z, ring A and the dashed lines are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.
    本发明提供了一个如下所述的化合物作为治疗或预防由淀粉样β蛋白的产生、分泌或沉积引起的疾病的药物。式(I)的化合物:其中R1、R2a、R2b、R3、R4、R5a、R5b、R6a、R6b、X、Y、Z、环A和虚线在说明书中定义,其药用可接受的盐或其溶剂化合物。
  • FUSED AMINODIHYDROPYRIMIDINE DERIVATIVE
    申请人:Masui Moriyasu
    公开号:US20130210839A1
    公开(公告)日:2013-08-15
    The present invention provides, for example, the following compound: wherein ring A is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, X 1 —X 2 ═X 3 is CR 5 —CR 6 ═CR 7 , N—CR 6 ═CR 7 , CR 5 —N═CR 7 or CR 5 —CR 6 ═N, R 1 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, R 2a and R 2b are each independently hydrogen, substituted or unsubstituted alkyl or the like, R 4a , R 4b , R 5 , R 6 and R 7 are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl or the like, its pharmaceutically acceptable salt or a solvate thereof having an effect of inhibiting amyloid β production, especially a BACE1 inhibitory activity, and useful as a medicament for treating diseases induced by production, secretion or deposition of amyloid β proteins.
    本发明提供了如下化合物:其中环A是取代或未取代的碳环或取代或未取代的杂环,X1—X2═X3为CR5—CR6═CR7,N—CR6═CR7,CR5—N═CR7或CR5—CR6═N,R1为取代或未取代的烷基,取代或未取代的烯基等,R2a和R2b各自独立为氢,取代或未取代的烷基等,R4a,R4b,R5,R6和R7各自独立为氢,卤素,羟基,取代或未取代的烷基等,其药学上可接受的盐或其溶剂化合物具有抑制淀粉样蛋白β产生的作用,特别是BACE1抑制活性,并可用作治疗由淀粉样蛋白β蛋白产生、分泌或沉积引起的疾病的药物。
  • NAPHTHYRIDINE DERIVATIVE
    申请人:Mitsuoka Yasunori
    公开号:US20130217705A1
    公开(公告)日:2013-08-22
    The present invention provides, for example, the following compound: wherein ring Z is pyridine or a carbocycle, each of which is substituted or unsubstituted, ring A is a carbocycle or a heterocycle, each of which is substituted or unsubstituted, R 1 is substituted or unsubstituted alkyl or the like, R 2a , R 2b , R 4a and R 4b are each independently hydrogen or substituted or unsubstituted alkyl or the like, its pharmaceutically acceptable salt or a solvate thereof having an effect of inhibiting amyloid β production, especially a BACE1 inhibitory activity, and useful as a medicament for treating diseases induced by production, secretion or deposition of amyloid β proteins.
    本发明提供了以下化合物:其中环Z是吡啶或碳环,每个都是取代或未取代的,环A是碳环或杂环,每个都是取代或未取代的,R1是取代或未取代的烷基或类似物,R2a、R2b、R4a和R4b分别独立地是氢或取代或未取代的烷基或类似物,其药学上可接受的盐或其溶剂化合物具有抑制淀粉样蛋白β产生的作用,特别是BACE1抑制活性,并且作为治疗由淀粉样蛋白β蛋白的产生、分泌或沉积引起的疾病的药物而有用。
查看更多

同类化合物

硫化丙烯 环硫乙烷 异丁烯硫醚 反式-2,3-二乙炔基-噻丙环 乙烯基噻丙环 9-硫杂双环[6.1.0]壬-4-烯 8-硫杂双环[5.1.0]辛烷 3,4-环硫丁腈 2-(氯甲基)环硫乙烷 2,2,3-三甲基噻丙环 1-硫杂-螺[2.7]癸烷 1-氰基-3,4-环硫丁烷 1,3-壬二烯-1-基噻丙环 1,2-环硫-5-己烯 (甲氧基甲基)噻丙环 (S)-(-)-己基硫氯丙烷 (S)-(-)-1,2-环硫十二烷 1-tert-butoxy-3-methyl-siletane (2S,5R)-2,5-Bis-chloromethyl-2,5-dimethyl-[1,4]dithiane (2-chloro-3-butenyl)-thiirane 2-tert.-Butyl-2,3-dimethyl-thiiran 2,5-Bis-(cyan-methyl)-1,4-dithian 2,2,4,4-tetrakis(trifluoromethyl)thietane <2-Brom-allyl>-<2,3-epithio-propyl>-aether 1,7-Bis-(3,3-dimethyl-but-1-ynyl)-8,9-bis-[2,2-dimethyl-prop-(Z)-ylidene]-2,6-dithia-bicyclo[5.2.0]nonane (2S,3S)-2,3-epithio-1-hexanol nona-Si-methyl-Si,Si',Si''-[1,3,5,7]tetrathiocane-2,2,6-triyl-tris-silane 2-Methylthio-2-ethylthiiran 2,3,4,4-tetrachloro-2,3,5,5-tetrafluorothiolane 2-Diethoxymethyl-2-isopropyl-thiirane 2,4,6-tris-(7-methylamino-heptyl)-[1,3,5]trithiane, trihydrochloride 2-(1-Ethyl-pentyl)-thiirane (2R,3R)-2,3-epithio-3-cyclohexyl-1-propanol 2,3-epithio-2-methyl-pentan-1-ol N-tert-butyl-4,6,6-trimethylcyclohex-3-en-1-amine cis-2,3-Di-tert.-butylthiiran 2,2-diethylthiirane 9-aza-1-thioniabicyclo<3.3.>nonane triiodide (2R,3S)-2,3-epithio-1-undecanol 3,3'-Bithietanyliden trans-2,5-Dibrom-1,4-dithian Thioglycidylthiocyanat 2,4,6-tri-tert-butyl-1,3,5-trithiane (R)-Thiirancarbonsaeure 2-[(2,2,2-trifluoroethoxy)methyl]thiirane (R)-(+)-methylthiirane (E)-1,2-epithio-3-undecene 2,5-di-tert.-Butylthiophan 2,4,6-triundecyl-1,3,5-trithiane (r)-2,4,6-tri-tert-butyl-1,3,5-trithiane